DrugDashboards

ropinirole

ropinirole · ROPINIROLE HYDROCHLORIDE 1 mg/1 · Tablet, Film Coated · Oral · Accord Healthcare Inc.

NDC 16729-0234-01 · 100 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →

The short version

10 companies supply this market — deep enough that no single failure threatens the supply. The price is down 10% over the past year, to $0.0515 per unit.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 62332-0032-31) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$0.1378per unit
middle half $0.0955–$0.2460 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $0.1378
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 2 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$0.025$0.05$0.075Nov 2018Jul 2024$0.0515
69 price points · per · last surveyed Invalid Date · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

WAC per package, as filed
$14.00
Reported to Texas DSHS · 2024 annual filing · Accord Healthcare, Inc

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2024)

$3,223
250 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for ropinirole (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA204022
TE code
AB
Approval date
Feb 28, 2017
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class II · TerminatedFeb 7, 2023
    Accord Healthcare, Inc. — CGMP Deviations: recalling drug products following an FDA inspection.
  • Class II · TerminatedFeb 7, 2023
    Accord Healthcare, Inc. — CGMP Deviations: recalling drug products following an FDA inspection.
  • Class II · TerminatedFeb 7, 2023
    Accord Healthcare, Inc. — CGMP Deviations: recalling drug products following an FDA inspection.
  • Class II · TerminatedFeb 7, 2023
    Accord Healthcare, Inc. — CGMP Deviations: recalling drug products following an FDA inspection.
  • Class II · TerminatedFeb 7, 2023
    Accord Healthcare, Inc. — CGMP Deviations: recalling drug products following an FDA inspection.
  • Class II · TerminatedFeb 7, 2023
    Accord Healthcare, Inc. — CGMP Deviations: recalling drug products following an FDA inspection.
  • Class II · TerminatedFeb 7, 2023
    Accord Healthcare, Inc. — CGMP Deviations: recalling drug products following an FDA inspection.

Manufacturers of ropinirole (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
Bryant Ranch PrepackROPINIROLE HYDROCHLORIDE 2 mg/1Jul 15, 2026Sep 3, 2026
Remedyrepack Inc.ROPINIROLE HYDROCHLORIDE .5 mg/1Jul 15, 2026Sep 3, 2026
A-S Medication SolutionsROPINIROLE HYDROCHLORIDE 1 mg/1Jul 15, 2026Sep 2, 2026
A-S Medication SolutionsROPINIROLE HYDROCHLORIDE 4 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.ROPINIROLE HYDROCHLORIDE 1 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.ROPINIROLE HYDROCHLORIDE .25 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.ROPINIROLE HYDROCHLORIDE 4 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.ROPINIROLE HYDROCHLORIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.ROPINIROLE HYDROCHLORIDE .5 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.ROPINIROLE HYDROCHLORIDE 2 mg/1Jul 15, 2026Sep 2, 2026
Accord Healthcare Inc.ROPINIROLE HYDROCHLORIDE 3 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals Inc.ROPINIROLE HYDROCHLORIDE 2 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals Inc.ROPINIROLE HYDROCHLORIDE .25 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals Inc.ROPINIROLE HYDROCHLORIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals Inc.ROPINIROLE HYDROCHLORIDE .5 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals Inc.ROPINIROLE HYDROCHLORIDE 4 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals Inc.ROPINIROLE HYDROCHLORIDE 1 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals Inc.ROPINIROLE HYDROCHLORIDE 3 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedROPINIROLE HYDROCHLORIDE 1 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedROPINIROLE HYDROCHLORIDE 2 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedROPINIROLE HYDROCHLORIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedROPINIROLE HYDROCHLORIDE 3 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedROPINIROLE HYDROCHLORIDE 4 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedROPINIROLE HYDROCHLORIDE .25 mg/1Jul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedROPINIROLE HYDROCHLORIDE .5 mg/1Jul 15, 2026Sep 2, 2026
Asclemed Usa Inc.ROPINIROLE HYDROCHLORIDE .5 mg/1Jul 15, 2026Sep 2, 2026
Asclemed Usa Inc.ROPINIROLE HYDROCHLORIDE .25 mg/1Jul 15, 2026Sep 2, 2026
Asclemed Usa Inc.ROPINIROLE HYDROCHLORIDE 1 mg/1Jul 15, 2026Sep 2, 2026
Asclemed Usa Inc.ROPINIROLE HYDROCHLORIDE 2 mg/1Jul 15, 2026Sep 2, 2026
Bionpharma Inc.ROPINIROLE HYDROCHLORIDE 1 mg/1Jul 15, 2026Sep 2, 2026
Bionpharma Inc.ROPINIROLE HYDROCHLORIDE 4 mg/1Jul 15, 2026Sep 2, 2026
Bionpharma Inc.ROPINIROLE HYDROCHLORIDE .25 mg/1Jul 15, 2026Sep 2, 2026
Bionpharma Inc.ROPINIROLE HYDROCHLORIDE .5 mg/1Jul 15, 2026Sep 2, 2026
Bionpharma Inc.ROPINIROLE HYDROCHLORIDE 5 mg/1Jul 15, 2026Sep 2, 2026
Bionpharma Inc.ROPINIROLE HYDROCHLORIDE 3 mg/1Jul 15, 2026Sep 2, 2026
Bionpharma Inc.ROPINIROLE HYDROCHLORIDE 2 mg/1Jul 15, 2026Sep 2, 2026
Bryant Ranch PrepackROPINIROLE HYDROCHLORIDE .25 mg/1Jul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCROPINIROLE HYDROCHLORIDE .25 mg/1Jul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCROPINIROLE HYDROCHLORIDE 1 mg/1Jul 15, 2026Sep 2, 2026
Coupler LLCROPINIROLE HYDROCHLORIDE 2 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "ropinirole — NDC 16729-0234-01," retrieved September 3, 2026, https://drugdashboards.com/drug/16729023401.

Free to cite with attribution — see how the data is put together.